United States News Todas as matérias

Kevin Rudd will step down as Australia's ambassador to the United States at the end of March, a year earlier than scheduled.

Biodesix (NASDAQ:BDSX) shares surged in early Monday trading after the lung diagnostics firm reported preliminary 2025 revenue that eclipsed its own upwardly revised guidance.

The company’s focus on high-margin lung cancer testing and a strategic expansion into primary care drove a 41% revenue spike in the fourth quarter.

Karyopharm Therapeutics (NASDAQ:KPTI) is entering a pivotal year for its oncology pipeline, with the company forecasting a duo of high-stakes clinical trial readouts that could redefine its market position as its current cash runway nears its end.

Boston Scientific Corp. (NYSE:BSX) has entered into a definitive agreement to acquire Valencia Technologies Corp., a private medical technology firm, in a strategic move to dominate the high-growth market for overactive bladder treatments.

Paramount Skydance (NASDAQ:PSKY) escalated its hostile pursuit of Warner Bros. Discovery (NYSE:WBD) on Monday, filing a lawsuit in Delaware to force the disclosure of financial details surrounding Netflix's (NASDAQ:NFLX) $82.7 billion rival bid.

In a move that reshapes the competitive landscape of Silicon Valley, Alphabet (NASDAQ:GOOGL) and Apple (NASDAQ:AAPL) have entered into a multi-year partnership to base the next generation of Apple’s artificial intelligence on Google’s Gemini models.

Alphabet (NASDAQ:GOOGL) vaulted to a $4 trillion market valuation on Monday, completing a dramatic narrative shift from a company once accused of losing its step in the artificial intelligence race to the world's second-most valuable public firm.

BioAge Labs (NASDAQ:BIOA) shares climbed Monday after the longevity-focused biotech reported that its experimental oral drug, BGE-102, sharply reduced systemic inflammation in a mid-stage study of obese patients.

The ONE Group Hospitality (NASDAQ:STKS) reported preliminary 2025 revenue of approximately $805 million on Monday, marking a 20% increase as the company digests its transformational acquisition of Benihana.

Nuvation Bio (NYSE:NUVB) reported preliminary 2025 revenue that beat internal projections, driven by the rapid adoption of its flagship lung cancer treatment, IBTROZI®.

Masimo Corp. (NASDAQ:MASI) reported preliminary 2025 results that landed at the high end of its guidance, signaling a successful first year under the leadership of Chief Executive Officer Katie Szyman.

Meta Platforms (NASDAQ:META) named Dina Powell McCormick as its new president and vice chairman on Monday, a major leadership pivot that brings a veteran of global finance and Republican politics into the center of the company’s multi-billion-dollar artificial intelligence expansion.

Shares in major U.S. lenders plummeted Monday morning after President Donald Trump blindsided the financial sector with a proposed 10% ceiling on credit card interest rates.

Amphenol Corp. (NYSE:APH) completed its acquisition of CommScope’s Connectivity and Cable Solutions (CCS) business on Monday, a transformational $10.5 billion deal that cements its position as a dominant provider of the hardware underpinning the artificial intelligence revolution.

Planet Fitness (NYSE:PLNT) reported a surge in year-end membership and same-club sales for 2025, signaling that its low-cost "Judgment Free Zone" model is continuing to capture market share among younger, budget-conscious consumers.

S&P Global (NYSE:SPGI) finalized the sale of its Enterprise Data Management (EDM) and thinkFolio businesses to private equity firm STG on Monday, concluding a divestiture aimed at sharpening the financial giant's focus on its core growth adjacencies.

Lipocine (NASDAQ:LPCN) experimental oral treatment for postpartum depression passed its final independent safety review, clearing the path for a critical data readout later this spring.

Hyperfine (NASDAQ:HYPR), the medical technology firm behind the first portable, AI-powered brain imaging system, reported a dramatic surge in fourth-quarter revenue, signaling a potential turning point for its bedside MRI technology.

Moderna (NASDAQ:MRNA) projected 2025 sales at the upper end of its forecast as a smaller-than-expected decline in U.S. vaccination rates and aggressive cost-cutting help the biotech giant navigate the post-pandemic landscape.

KORU Medical Systems (NASDAQ:KRMD) reported preliminary 2025 revenue that exceeded the high end of its guidance on Monday, as the medical technology firm prepares to pivot from its core immunology business into the high-growth oncology market.

Cellares and Cabaletta Bio (NASDAQ:CABA) announced a landmark regulatory achievement Monday, with the FDA clearing an Investigational New Drug (IND) Amendment to manufacture the autoimmune-focused CAR T therapy, rese-cel, using Cellares’ fully automated platforms.

GeneDx Holdings Corp. (NASDAQ:WGS) issued a bullish outlook for 2026 on Monday, forecasting revenue to exceed the half-billion-dollar milestone as the company’s pivot to high-margin exome and genome sequencing gains unprecedented traction.

DexCom (NASDAQ:DXCM) projected its annual revenue will climb toward $5.25 billion in 2026, marking a pivotal year for the glucose-monitoring leader as it phases out older hardware in favor of its longest-lasting sensor technology to date.

AbbVie (NYSE:ABBV) secured exclusive global rights to a novel cancer-fighting antibody from RemeGen Co. on Monday, marking one of the year’s largest oncology licensing agreements as the pharmaceutical giant moves to integrate next-generation bispecifics with its expanding "ADC" platform.